European Commission Approves KEYTRUDA® (pembrolizumab)

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 16, 2023--

Related Keywords

Norway , United States , Liechtenstein , Canada , Iceland , Switzerland , American , Solange Peters , Gregory Lubiniecki , Peter Dannenbaum , Damini Chokshi , Julie Cunningham , Statement Of Merck Co Inc , Instagram , Merck Research Laboratories , Merck Co Inc , European Organisation For Research , Centre Hospitalier Universitaire Vaudois , Facebook , Twitter , Linkedin , Youtube , Exchange Commission , European Commission , American Joint Committee On Cancer , Committee For Medicinal Products Human , Medicinal Products , Human Use , American Joint Committee , Merck Research , European Organisation , European Thoracic Oncology Platform , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Bacillus Calmette Guerin , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Looking Statement , Securities Litigation Reform Act , Annual Report , Prescribing Information , Medication Guide , Media Contacts , Business Wire , Business ,